Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CIML NK Cells in Relapsed/Refractory AML and MDS
NCT04893915Phase 2Withdrawn
- Sponsor
- Washington University School of Medicine
- Start
- Jun 2022
- Primary completion
- Dec 2024
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Lymphokine-Activated Killer Cells
01
Overview
A Phase 2 trial of cytokine-induced memory-like natural killer cells in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), sponsored by Washington University School of Medicine. Planned start Jun 2022; status: withdrawn.
02
Drugs
cytokine-induced memory-like natural killer cells
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT04893915.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04893915.